General description
Neuropilin-2 (UniProt: O60462; also known as Vascular endothelial cell growth factor 165 receptor 2) is encoded by the NRP2 (also known as VEGF165R2) gene (Gene ID: 8828) in human. Neuropilins are non-tyrosine kinase cell surface glycoproteins expressed in all vertebrates and widely conserved across species. The two isoforms, neuropilin-1 (NRP1) and neuropilin-2 (NRP2), mainly act as co-receptors for VEGF165 and VEGF145, semaphorins 3C, 3F, and the PLGF-2 isoform of PGF. Neuropilin-2 is a single-pass type I membrane protein that is synthesized with a signal peptide (aa 1-20) that is subsequently cleaved in the mature form. It has an extracellular domain (aa 21-864), a transmembrane domain (aa 865-889), and cytoplasmic tail (aa 890-931). It contains two CUB domains (aa 28-142 and 149-267) that mediate its binding to semaphorin. It also has two F5/8 type -C domains that are responsible for binding to heparin and VEGF. Six different isoforms of Neuropilin-2 have been described that are produced by alternative splicing. Neuropilin-2 levels are often up-regulated in various cancers where they increase the oncogenic activities of malignant cells by promoting survival, inducing angiogenesis and lymphangiogenesis, and contributing to therapy resistance. In non small cell lung cancer (NSCLC) cell lines, TGF-β signaling is reported to preferentially increase the abundance of NRP2b isoform. Although it has been shown that the presence of NRP2b inhibits the proliferation of cultured cells and diminishes primary tumor growth, it also enhances cellular migration, invasion into Matrigel, and tumorsphere formation in cultured cells in response to TGF-β. In addition, it is shown to promote metastasis in xenograft murine models. In lung cancer cell lines, knocking down of NRP2 is shown to impair both baseline and TGF-β-induced migration and invasion. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonal. (Ref.: Roy, S., et al. (2017). Front. Immunol. 8: 1228; Gemmill, RM., et al., (2017). Sci. Signal. 10, eaag0528).
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Immunogen
His-tagged recombinant fragment corresponding to 209 amino acids from the extracellular domain within the C-terminal half of human Neuropilin-2.
Application
Quality Control Testing
Evaluated by Western Blotting in Human umbilical vein endothelial cell (HUVEC) lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Neuropilin-2 in Human umbilical vein endothelial cell (HUVEC) lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Neuropilin-2 in bEND.3 cell lysates.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Neuropilin-2 in A549 cells.
Affinity Binding Assay: A representative lot of this antibody bound recombinant fragment of Human Neuropilin-2 with a KD of 4.0 x 10-9 in an affinity binding assay.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Neuropilin-2 in Human uterus and Human placenta tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Biochem/physiol Actions
Clone 1D15 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects Neuropilin-2. It targets an epitope within the extracellular domain.
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Preparation Note
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Reconstitute lyophilized antibody pellet with 25μL of ultrapure water or Phosphate Buffered Saline (PBS). Please refer to our
reconstitution protocol and the specific application guidance on the suggested starting dilutions and sample type.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.